

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

02 Jun 2026

### Study of the potential radioprotective effects of probiotic bacteria to mitigate gastrointestinal complications of colorectal cancer after conventional radiotherapy

#### Protocol summary

##### Study aim

Evaluation of the effect of probiotic bacteria on quality of life, blood factors and reduction of gastrointestinal complications after conventional radiotherapy procedures in patients with colorectal cancer

##### Design

This is a double-blind randomized clinical trial study. Randomization will be done by computer software. 60 patients with colorectal cancer will be selected in the study. Patients will be divided to receive probiotic supplements or placebo.

##### Settings and conduct

This clinical trial will be performed in the oncology radiotherapy unit of Namazi Hospital in Shiraz. Patients with colorectal cancer will be divided in one of the probiotic or placebo groups.

##### Participants/Inclusion and exclusion criteria

Admission criteria are adults who have colorectal cancer (colon and rectum) and will be treated with radiotherapy and their age is 18 to 90 years. Exclusion criteria include the use of narcotic analgesics, acute and chronic gastrointestinal complications before treatment, use of any antibiotics in a week before the start of radiotherapy unless prescribed by a doctor, dissatisfaction with continued treatment, non-adherence to the treatment regimen, Do not use any probiotic supplements, including probiotic yogurt for 15 days before starting treatment, do not use anti-diarrheal drugs (unless prescribed by a doctor) and do not receive radiation therapy in the abdomen and pelvis in previous years.

##### Intervention groups

Group 1: 2 probiotic capsules daily from one week before the start of treatment to ten days after the end of treatment  
Group 2: 2 probiotic capsules daily from one week after the start of treatment to ten days after the end of treatment  
Group 3: 2 probiotic placebo capsules daily

#### Main outcome variables

Quality of life, Gastrointestinal symptoms, Blood factors

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20210704051788N1**

Registration date: **2021-10-10, 1400/07/18**

Registration timing: **prospective**

Last update: **2021-10-10, 1400/07/18**

Update count: **0**

##### Registration date

2021-10-10, 1400/07/18

##### Registrant information

##### Name

Hamidreza Jamali

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 71 3234 9332

##### Email address

jamalihamidreza91@yahoo.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2021-10-12, 1400/07/20

##### Expected recruitment end date

2022-02-09, 1400/11/20

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**  
empty

**Scientific title**  
Study of the potential radioprotective effects of probiotic bacteria to mitigate gastrointestinal complications of colorectal cancer after conventional radiotherapy

**Public title**  
Study of the potential radioprotective effects of probiotic bacteria to mitigate gastrointestinal complications after conventional radiotherapy

**Purpose**  
Treatment

**Inclusion/Exclusion criteria**  
**Inclusion criteria:**  
Adults with colorectal cancer who are candidates for radiotherapy as part of their treatment  
**Exclusion criteria:**  
Consumption of narcotic painkillers Existence of acute and chronic gastrointestinal complications before starting treatment Take any antibiotics one week before the start to end of radiotherapy Received radiation therapy in the abdomen and pelvis in recent years Use probiotic supplements during the 15 days before the study and also take other probiotic forms including probiotic yogurt and other fermented foods

**Age**  
From **18 years** old to **90 years** old

**Gender**  
Both

**Phase**  
3

**Groups that have been masked**

- Participant
- Investigator
- Outcome assessor

**Sample size**  
Target sample size: **60**

**Randomization (investigator's opinion)**  
Randomized

**Randomization description**  
Participants are randomly assigned to three groups to receive probiotics one week before the start of radiotherapy (n = 20), one week after the start of radiotherapy (n = 20) or placebo (n = 20).

**Blinding (investigator's opinion)**  
Double blinded

**Blinding description**  
Randomization will be hidden from researchers and participants until the statistical analysis is completed. Another person who has no role in this clinical trial and is not aware of random allocation gives the capsules to participants.

**Placebo**  
Used

**Assignment**  
Parallel

**Other design features**  
Participants will take probiotics for up to ten days after

completing radiotherapy

## Secondary Ids

empty

## Ethics committees

1

### Ethics committee

#### Name of ethics committee

Ethics committee of Shiraz University of Medical Sciences

#### Street address

Central building of Shiraz University of Medical Sciences -Zand Blvd

#### City

Shiraz

#### Province

Fars

#### Postal code

۷۱۳۴۸۱۴۳۳۶

### Approval date

2021-09-11, 1400/06/20

### Ethics committee reference number

IR.SUMS.REC.1400.457

## Health conditions studied

1

### Description of health condition studied

Colorectal Cancer

### ICD-10 code

C18

### ICD-10 code description

Malignant neoplasm of colon

2

### Description of health condition studied

Colorectal Cancer

### ICD-10 code

C20

### ICD-10 code description

Malignant neoplasm of rectum

## Primary outcomes

1

### Description

Quality of life

### Timepoint

At the beginning of the study and 8 weeks after the intervention

### Method of measurement

Questionnaire

## 2

### **Description**

Gastrointestinal disorders

### **Timepoint**

At the beginning of the study and 6 months after the intervention

### **Method of measurement**

Clinical examination by an oncologist

## **Secondary outcomes**

## 1

### **Description**

Thrombocytopenia-Leukopenia-Anemia

### **Timepoint**

At the beginning of the study and 8 weeks after the intervention

### **Method of measurement**

CBC Test(Complete blood count)

## **Intervention groups**

## 1

### **Description**

Intervention group: 1-Patients will take two capsules (daily) containing several probiotic strains from one week before the start of treatment until 10 days after the end of radiotherapy.

### **Category**

Treatment - Drugs

## 2

### **Description**

Intervention group: 2-Patients will take two capsules (daily) containing several probiotic strains from one week after the start of treatment to 10 days after the end of radiotherapy.

### **Category**

Treatment - Drugs

## 3

### **Description**

Control group: Two placebo capsules daily for ten days after the end of radiotherapy

### **Category**

Placebo

## **Recruitment centers**

## 1

### **Recruitment center**

#### **Name of recruitment center**

Namazi hospital

#### **Full name of responsible person**

Dr.Hamid Nasrollahi

#### **Street address**

Namazi Hospital-Namazi Sq.

#### **City**

Shiraz

#### **Province**

Fars

#### **Postal code**

7193613311

#### **Phone**

+98 71 3647 4332

#### **Email**

nemazee\_inf@sums.ac.ir

#### **Web page address**

<https://namazi.sums.ac.ir/>

## **Sponsors / Funding sources**

## 1

### **Sponsor**

#### **Name of organization / entity**

Shiraz University of Medical Sciences

#### **Full name of responsible person**

Dr. Abbas Rezaeianzadeh

#### **Street address**

Zand Blvd - Medical School

#### **City**

Shiraz

#### **Province**

Fars

#### **Postal code**

7134814336

#### **Phone**

+98 71 3230 5410

#### **Email**

vcrdep@sums.ac.ir

#### **Web page address**

#### **Grant name**

#### **Grant code / Reference number**

22054

#### **Is the source of funding the same sponsor organization/entity?**

Yes

#### **Title of funding source**

Shiraz University of Medical Sciences

#### **Proportion provided by this source**

100

#### **Public or private sector**

Public

#### **Domestic or foreign origin**

Domestic

#### **Category of foreign source of funding**

*empty*

#### **Country of origin**

#### **Type of organization providing the funding**

Academic

## **Person responsible for general inquiries**

### **Contact**

#### **Name of organization / entity**

Shiraz University of Medical Sciences

#### **Full name of responsible person**

Hamidreza Jamali

**Position**

Master of Medical Physics

**Latest degree**

Master

**Other areas of specialty/work**

Medical Physics

**Street address**

Department of Medical Physics,7th floor, School of  
Medicine,Zand Blvd.

**City**

Shiraz

**Province**

Fars

**Postal code**

7134814336

**Phone**

+98 71 3234 9332

**Email**

jamalihamidreza91@yahoo.com

## Person responsible for scientific inquiries

**Contact**

**Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Dr. Seyed Mohammad Javad Mortazavi

**Position**

Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Medical Physics

**Street address**

Department of Medical Physics, 7th floor, School of  
Medicine, Zand Blvd.

**City**

Shiraz

**Province**

Fars

**Postal code**

7134814336

**Phone**

+98 71 3208 3363

**Email**

mortazavismj@gmail.com

## Person responsible for updating data

**Contact**

**Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Hamidreza Jamali

**Position**

Master of Medical Physics

**Latest degree**

Master

**Other areas of specialty/work**

Medical Physics

**Street address**

Department of Medical Physics,7th floor, School of  
Medicine,Zand Blvd.

**City**

Shiraz

**Province**

Fars

**Postal code**

7134814336

**Phone**

+98 71 3234 9332

**Email**

jamalihamidreza91@yahoo.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to  
make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to  
make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to  
make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to  
make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to  
make this available

**Title and more details about the data/document**

All data can be shared without personal information

**When the data will become available and for how long**

6 months after the publication of the results will be given  
access

**To whom data/document is available**

It will be available to researchers working in academic  
and scientific institutions

**Under which criteria data/document could be used**

All requests will be reviewed by the person in charge of  
public responses

**From where data/document is obtainable**

All applicants should send their request to  
jamalihamidreza91@yahoo.com

**What processes are involved for a request to access data/document**

Requests will be processed within two weeks and the  
response will be emailed to the applicant.

**Comments**